Budget impact analysis of gene expression tests to aid therapy decisions for breast cancer patients in Germany.

•Breast cancer therapy causes high costs to German healthcare payers and society.•Use of Oncotype DX reduces breast cancer therapy costs versus standard care.•Savings result from lower adjuvant chemotherapy use after testing with Oncotype DX.•Use of other tests increases chemotherapy use and costs versus standard care.